Figure 5. (A) Endoscopic polyp score reduction is inversely correlated with the number of allergen skin prick tests positives (P=0.023) such that in 100% (5/5) patients with 2 or less positive SPT benralizumab treatment reduced polyp size. (B) In contrast, 100% (4/4) of patients with blood eosinophil counts greater than 700/µl improved, although correlation was not significant (P=0.301). Four-parameter logistic curves interpolate the correlation inflection points of each graph.
If we divide the absolute blood eosinophil count by the number of positive allergen skin prick tests (Eos/SPT), the ratio appears to be a good predictor of benralizumab induced endoscopic nasal polyp score reduction (P=0.005). In other words, we found that high baseline eosinophil count and low number of positive allergen skin prick tests correlates with better benralizumab induced nasal polyp score reduction as seen in Figure 6A. Similarly, the ratio of blood eosinophil count to SPT correlates with benralizumab induced CT scan polyp score reduction, and this too was statistically significant (P=0.048) as shown in Figure 6B. These preliminary findings in a small group of highly selected patients may suggest that there is a relationship between allergy skin testing, blood eosinophil count and benralizumab induced nasal polyp reduction.